Leucine/nicotinic acid - NuSirt Biopharma
Alternative Names: Leucine/niacin; Niacin/leucine; Nicotinic acid/leucineLatest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator NuSirt Biopharma
- Class Branched-chain amino acids; Essential amino acids; Nicotinic acids; Small molecules; Vitamins
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA (PO)
- 08 Sep 2020 Leucine/ Nicotinic acid is still in preclinical trials for Atherosclerosis in USA (NuSirt Biopharma pipeline, September 2020)